If you have searched “TB-500 cost” and come away more confused than when you started, that is the correct reaction. One site quotes $12 a vial, the next quotes $500 a month, and a clinic down the road wants $795 for a “cycle.” None of those numbers is wrong, and none of them is comparable to the others. They are prices for different things.
This page explains why, breaks the cost into the parts that actually drive it, and walks the real US routes as they stand in mid-2026. It does not give dosing, sourcing, or protocols — only how the money works.
Why there’s no single TB-500 price
Most compounds on this site have at least one clean reference price: a pharmacy-compounded version, prescribed after an evaluation and filled by a licensed pharmacy, against which the gray-market price can be compared. TB-500 is unusual in that, for most of its history, that clean tier has barely existed.
TB-500 grew up almost entirely in the research-chemical lane. It is a synthetic fragment of thymosin beta-4 that has been sold for years as a laboratory compound, not as a pharmacy-compounded medication. Because the FDA placed it in 503A Category 2 in 2023 — flagged for significant safety concerns for compounding — compounding pharmacies had little reason to build a TB-500 line. On April 15, 2026 it was removed from Category 2 (the original nominations were withdrawn), but removal is procedural and does not authorize compounding on its own. It now sits in a gray zone pending a Pharmacy Compounding Advisory Committee review on July 23, 2026.
The practical consequence for pricing is blunt: the most regulated, most reliable version of TB-500 — a prescribed, pharmacy-verified product — is the version that is hardest to find and price right now. So the figures circulating online overwhelmingly describe the other tiers, and they describe them as if they were equivalent. They are not.
The core idea: with TB-500, price tracks the legitimacy and oversight of the channel, not the molecule. The same seven-amino-acid fragment can cost $15 or $400 depending on whether anyone licensed is standing behind it.
The four things you’re actually paying for
A TB-500 invoice — wherever it comes from — bundles up to four separate costs, and the cheap headline numbers strip most of them out.
The medication itself is the smallest line item. The raw compound is inexpensive to produce, which is why research vials can be advertised so cheaply. If the price is only the molecule, you are paying for almost nothing else.
The prescriber relationship is usually the largest. An evaluation, a clinician’s time and liability, the decision to treat, and follow-up review are what separate a clinical program from a vial in the mail. This is most of what a clinic or telehealth program is charging for.
Labs and monitoring are variable but real in a legitimate program — baseline and follow-up bloodwork add cost a research vial never includes.
Channel legitimacy is the invisible line item. A prescription filled by a licensed pharmacy, against a verified product, carries a cost that a research-use vendor simply does not. When a price looks impossibly low, this is the component that has been removed.
Route by route in 2026
Research-use-only vials (the cheapest, and not a patient route)
This is where almost all the eye-catching low numbers come from. Research vendors advertise TB-500 from roughly $12 to $50 per vial depending on size and seller. It is sold “for research use only,” with no prescriber, no pharmacy, no oversight, and — critically — no guarantee of identity, purity, or concentration. The low price is not a discount on a medication; it is the price of a laboratory chemical with everything clinical stripped away. This lane is not a legitimate patient route, and the savings are not what they appear (see below).
Telehealth and “Wolverine Stack” programs
Here TB-500’s second quirk shows up: it is rarely sold by itself. The dominant commercial form is the “Wolverine Stack,” TB-500 bundled with BPC-157, marketed for recovery. Telehealth programs that include TB-500 in this combination typically run about $200–$600 a month, often inclusive of a virtual consult, shipping, and basic monitoring. Some platforms advertise combination programs starting near $199/month.
The takeaway for budgeting is that a standalone “TB-500 monthly price” is largely fictional — you are usually pricing a two-peptide program, and TB-500’s individual share is hard to isolate from a bill dominated by the prescriber relationship. Budget for the program, not the molecule. (For the BPC-157 half of that bill, see the dedicated BPC-157 cost page.)
In-person clinics
A regenerative, sports-medicine, or anti-aging clinic offering TB-500 — again, usually as part of a stack — tends to price by cycle or package. Reported figures for combined BPC-157/TB-500 programs land around $400–$800, and a single Doral clinic, for example, lists a Wolverine Stack at $445 per cycle. You are paying for in-person evaluation, facility overhead, and clinical supervision on top of the medication.
The tier that’s missing
Notice what is absent from those three: a clean, standalone, pharmacy-compounded TB-500 price the way one exists for, say, sermorelin. In mid-2026 that tier is thin to nonexistent, which is why the market defaults to research vials and bundled stacks. That gap is the single most TB-500-specific fact about its cost.
The naming problem: what are you even paying for?
A pricing decision assumes you know what the product is. With TB-500 you may not. “TB-500” is a synthetic fragment of thymosin beta-4 — it is not the same thing as full-length thymosin beta-4 (the 43-amino-acid parent protein), and it is not thymosin alpha-1, a different immune-modulating peptide. The bulk of the human research people cite actually involves full-length thymosin beta-4, not the injected fragment sold as TB-500.
This matters for cost because a cheap vial and an expensive vial may not be the same substance, the same purity, or the same fragment. Comparing prices across vendors assumes a standardized product that does not reliably exist in the research lane. A low per-vial number is only a bargain if what is in the vial is what the label says — and in an unverified channel, that is exactly what you cannot confirm.
Why research-vial pricing isn’t the saving it looks like
It is tempting to treat the $15 vial as “TB-500, just cheaper.” It isn’t. The price difference between a research vial and a clinical program is not a markup on the same product — it is the cost of everything the vial leaves out: a licensed prescriber, a verified and pharmacy-handled product, sterility and identity assurance, and monitoring. Strip those away and of course the number falls.
Layered on top are the costs that don’t show on the sticker: there is no recourse if the product is underdosed, degraded, or mislabeled; gray-market injectables carry contamination and sterility risk; and TB-500 is prohibited in sport under the World Anti-Doping Agency’s growth-factor provisions, so for any tested athlete the “cost” includes a sanction risk no price tag reflects. The cheapest route is cheap precisely because it removes the things that make a medication safe to use.
Insurance, HSA/FSA, and why GLP-1s are different
For TB-500, insurance is simple: it covers none of it. Because TB-500 has no FDA-approved indication, no US insurer reimburses it, and the out-of-pocket figure is the entire cost. This is the standard situation for non-approved research peptides and stands in deliberate contrast to FDA-approved drugs — semaglutide, tirzepatide, tesamorelin, bremelanotide — which can be covered for their approved uses.
HSA and FSA funds generally cannot be applied either, since those require an eligible product tied to a diagnosed condition; an unapproved compound usually does not qualify. Rules vary by administrator, so confirm before assuming.
What July 2026 could change about the price
The honest forward-looking answer is: maybe something, but not soon, and not necessarily downward. If the July 23, 2026 PCAC review recommends adding TB-500 to the 503A Bulks List and the FDA follows through, licensed compounding pharmacies could prepare it against individual prescriptions — creating, for the first time, a real clean tier to price. The earliest that could translate into legal compounded access is late in 2026, and only if the vote is favorable; nothing is guaranteed.
Even then, TB-500’s thin compounding history works against quick price stability. Unlike BPC-157, which has a more established pharmacy-compounded ecosystem, TB-500 has almost none to build on, so a 503A supply chain and predictable pricing would likely lag. A door opening is not the same as a market forming.
This page is educational. Peptide Help USA does not sell, supply, or prescribe TB-500, and nothing here is dosing, sourcing, or medical advice. If you are weighing TB-500, the cost question is inseparable from the legitimacy question — start with how to get TB-500 legally and what a prescription actually involves before comparing any prices.
Frequently asked questions
How much does TB-500 cost in the US?
It depends entirely on the channel. Research-use vials are advertised from roughly $12 to $50 each, telehealth programs that bundle TB-500 with BPC-157 run about $200–$600 a month, and in-person clinic cycles often land at $400–$800. Those numbers are not comparable, because they buy very different things in terms of oversight and product reliability.
Does insurance cover TB-500?
No. TB-500 is not FDA-approved for any indication, so no US insurer covers it and the out-of-pocket cost is the whole cost. This is different from FDA-approved peptides such as semaglutide or tesamorelin, which can be covered for their approved uses.
Why is TB-500 so much cheaper from research vendors?
Because a research-use-only vial is not a prescribed, pharmacy-verified medication. It is sold for laboratory use, with no prescriber, no compounding pharmacy, no oversight, and no guarantee of what is actually in it. The low price reflects the absence of everything that makes the clinical version cost more.
Will TB-500 get cheaper after the July 2026 FDA review?
Not necessarily, and not quickly. The PCAC review on July 23, 2026 could eventually open a legal compounding pathway, but TB-500 has almost no history as a pharmacy-compounded product, so a 503A supply chain and stable pricing would take time to form even after a favorable vote.
Can I use an HSA or FSA to pay for TB-500?
Generally no. HSA and FSA funds are tied to treatment of a diagnosed condition with an eligible medical product. Because TB-500 has no FDA-approved indication, it usually does not qualify, though rules vary and you should confirm with your plan administrator.